Latest research on anti-RSV

Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)

anti-RSV dosage

Data on the clinical records of the mother and the child and the reason for indication of the anti-RSV prophylaxis were collected on the day of the first dose of palivizumab by means of a questionnaire applied to the parents, besides the analysis of a medical form that indicated the administration of the monoclonal antibody. [source, 2014]
In cases where there was a third mAb administration, anti-RSV was dosed instead (Table II) to reduce the likelihood of interference in mAb detection because of potential monkey anti-idiotype antibodies to anti-growth factor in circulation. [source, 2013]
Rabbit anti-RSV polyclonal sera were prepared by immunizing New Zealand white rabbits subcutaneously with a dose equivalent of 106 TCID50 of UV-inactivated, purified RSV-A2 in complete Freund’s adjuvant; rabbits were boosted two times with the same dose in incomplete Freund’s adjuvant every three weeks. [source, 2013]
In keeping with this hypothesis, we have recently demonstrated that LL-37 exhibits effective, dose-dependent and timing-specific anti-RSV activity in vitro in a number of cell lines [144]. [source, 2013]
Given the severity of his symptoms, he was treated with 5 days of aerosolized Ribavirin (Virazole 2 gm inhaled every 8 hours), one dose of IV immunoglobulin (Gamunex 400 mg/kg = 50,000 mg), and, due to financial constraints, a single half-dose of palivizumab (Synagis 7.5 mg/kg = 900 mg) [9]. [source, 2012]
On day 3 after infection, mice were i.p. treated with 300 µg/mouse anti-RSV G mAb 130-6D, mAb 232-1F [24], or 300 µg/mouse control normal mouse Immunoglobulin G (IgG) (Thermo Fisher Scientific), or for combination experiments, mAbs were administered either alone or in combination at suboptimal doses of 75 µg for mAb 131-2G, 150 µg for mAb 130-6D or 75–150 µg for control IgG. [source, 2012]
Immunization at all doses of unadjuvanted RSV F nanoparticles resulted in high titers of anti-RSV F serum antibody. [source, 2012]
After 7 days, when tumor volume reached 65-93 mm3 (n = 10 per group), cA10-A3 or Synagis as an isotype control at a dose of 10 mg/kg was injected intravenously three times per week for 28 days. [source, 2012]
The present study demonstrates that immunization with the capsid-modified Ad vector AdF.RGD compared to immunization with FIRSV, at doses inducing comparable levels of anti-RSV neutralizing and protective immunity, leads to a more pronounced RSV-specific Th1 response and does not prime for vaccine-induced enhanced RSV disease. [source, 2011]
Although no RSV vaccine exists, infants and children with risk factors for severe RSV infection (eg, lung disease or prematurity) can receive monthly doses of palivizumab, a humanized murine anti-RSV monoclonal antibody, during the RSV season. [source, 2011]